Bachor R, Hautmann R, Hasan T
Urologische Universitätsklinik, Ulm, Germany.
Urol Res. 1994;22(1):21-3. doi: 10.1007/BF00431544.
Photodynamic therapy (PDT) consists in administration of a photosensitizer and subsequent irradiation of the tumor with visible light. Routinely the photosensitizer is given intravenously (i.v.). The goal of our study was to examine whether intravesical (i.b.) instillation of the photosensitizer for PDT of bladder cancer might be feasible. Therefore, the uptake of chlor-aluminum-sulfonated phthalocyanine (CASPc) in bladder, bladder tumor, skin, and muscle in a rat bladder cancer model after i.v. injection and i.b. instillation was compared. The efficacy of PDT after either method of administration was also evaluated. The CASPc concentration in bladder tumor after i.v. injection was approximately 1.5-fold that after i.b. instillation. The ratio of CASPc concentration between bladder tumor and normal bladder was approximately 2:1 after administration by either route. There was no systemic absorption of CASPc after i.b. instillation; hence no systemic side effects are expected. PDT showed similar effects on bladder tumor after either method of administration, but less side effects on normal bladder wall after i.b. instillation. Our results demonstrate that i.b. instillation of CASPc for PDT of superficial bladder cancer seems to have advantages over i.v. injection.
光动力疗法（PDT）包括给予一种光敏剂，随后用可见光照射肿瘤。通常光敏剂通过静脉注射（i.v.）给药。我们研究的目的是检验膀胱内（i.b.）灌注光敏剂用于膀胱癌的光动力疗法是否可行。因此，比较了在大鼠膀胱癌模型中静脉注射（i.v.）和膀胱内灌注（i.b.）后，氯铝磺化酞菁（CASPc）在膀胱、膀胱肿瘤、皮肤和肌肉中的摄取情况。还评估了两种给药方法后光动力疗法的疗效。静脉注射后膀胱肿瘤中的CASPc浓度约为膀胱内灌注后的1.5倍。两种给药途径后，膀胱肿瘤与正常膀胱中CASPc浓度之比约为2:1。膀胱内灌注后没有CASPc的全身吸收；因此预计不会有全身副作用。两种给药方法后光动力疗法对膀胱肿瘤显示出相似的效果，但膀胱内灌注后对正常膀胱壁的副作用较小。我们的结果表明，膀胱内灌注CASPc用于浅表性膀胱癌的光动力疗法似乎比静脉注射更具优势。
